[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362310-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-362310-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","incidence-prevalence-survival-and-mortality-of-chronic-lymphocytic-leukaemiasmall-lymphocytic-lymphoma-and-waldenstrom-macroglobulinaemia-in-australia","Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia","","Background focuses on mature B-cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM), which are highly prevalent in older populations. The study quantifies incidence, prevalence, and relative survival and mortality in Australia and reports past trends. Registry cases from 2009–2018 were analysed for rates and projected to 2038 using linear regression, with Kaplan–Meier methods estimating survival from 2009–2018.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/incidence-prevalence-survival-and-mortality-of-chronic-lymphocytic-leukaemiasmall-lymphocytic-lymphoma-and-waldenstrom-macroglobulinaemia-in-australia/362310/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/incidence-prevalence-survival-and-mortality-of-chronic-lymphocytic-leukaemiasmall-lymphocytic-lymphoma-and-waldenstrom-macroglobulinaemia-in-australia/362310.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What study objective is addressed in the abstract?","Question",{"text":63,"@type":64},"To quantify incidence, prevalence, and relative survival and mortality for CLL/SLL and WM in Australia, and to report past trends.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which time period and data sources were used for analysis?",{"text":68,"@type":64},"Cases registered from January 2009 to December 2018 across Victoria, Tasmania, Australian Capital Territory, and Queensland were identified from registries.",{"name":70,"@type":61,"acceptedAnswer":71},"What survival outcomes were reported for CLL/SLL and WM?",{"text":72,"@type":64},"Kaplan–Meier estimates showed 10-year survival rates of 53% for CLL/SLL and 42% for WM at the end of the available data period (2018).",{"name":74,"@type":61,"acceptedAnswer":75},"How were incidence trends analysed and projected into the future?",{"text":76,"@type":64},"Incidence rates for 2009–2018 were calculated and then projected to 2038 using linear regression.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},362310,1790193544,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nIncidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia  \nDieu Nguyen1  | Shalika Bohingamu Mudiyanselage1 | Dipti Talaulikar2 | Fei-Li Zhao3  | Boxiong Tang4 | Mostafa Kamal1 | Lan Gao1   \n1Deakin University, Geelong, Victoria, Australia | 2Australian National University, Canberra, Australian Capital Territory, Australia | 3BeOne Medicines Ltd., Sydney, New South Wales, Australia | 4BeOne Medicines Ltd. , San Carlos, California, USA  \nCorrespondence: Fei-Li Zhao ([fei-li.zhao@beonemed.com](fei-li.zhao@beonemed.com)) | Lan Gao ([lan.gao@deakin.edu.au](lan.gao@deakin.edu.au))  \nReceived: 15 August 2024 | Revised: 24 November 2025 | Accepted: 17 January 2026  \nKeywords: CLL/SLL | incidence | lymphoid neoplasms | survival | WM  \nABSTRACT  \nBackground: Mature B-cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM) are highly prevalent in older populations.  \nAims: This study quantified the incidence, prevalence and relative survival/mortality rate in Australia for CLL/SS and WM and reported the past trends.  \nMaterials & Methods: All CLL/SLL and WM cases registered from January 2009 to December 2018 in Victoria, Tasmania, Australian Capital Territory and Queensland were identified. Incidence rates over the observed period (2009–2018) were calculated and then projected to 2038 using linear regression. Kaplan–Meier (KM) curves were used to estimate survival rates from 2009 to 2018.  \nResults: Between 2009 and 2018, the annual age-standardised incidence rates of CLL/SLL (range, 600.05–887.92 cases per 107 person-years) and WM (range, 41.48–78.19 cases per 107 person-years) showed an increasing trend (coefficient: 26.98 [p = 0.023] and 3.20 [p = 0.009], respectively). A similar trend was seen in age-standardised prevalence proportions by sex and age group. KM curves showed 10-year survival rates of 53%(CLL/SLL) and 42%(WM) at the end of the available data period (2018) . Differences in survival between sexes were not statistically significant in the log-rank test, but univariable analysis showed male sex and older age were associated with a higher risk of mortality in both condition.  \nDiscussion: The change in survival over time may reflect disease characteristics and recent advances in treatment. Conclusion: Given the increasing incidence and relatively high survival of CLL/SLL and WM, strategic planning for the future management is warranted in the context of Australia’s ageing population.  \n1 | Introduction  \nIn Western countries, chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL; CLL is cancer in the bloodstream; SLL is in the lymph node system [1–3]) is one of the most  \ncommon mature B-cell neoplasms. Lymphoplasmacytic lymphoma (of which 95% of cases are Waldenström macroglobulinaemia [WM]) is a rare type of non-Hodgkin lymphoma (NHL) characterised by bone marrow infiltration and monoclonal immunoglobulin M gammopathy in the blood that mostly affects  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71582 1 of 13  \n[https://doi.org/10.1002/cam4.71582](https://doi.org/10.1002/cam4.71582)  \nadults [1]. Both lymphoid neoplasms are frequently observed in the older population and are considered incurable, albeit with high survival rates. Per current guidelines, patients with asymptomatic CLL/SLL and WM are closely monitored [4–7] . For patients who require treatment, therapeutic options include anti-CD20 monoclonal antibody-based chemoimmunotherapy and newer agents such as Bruton Tyrosine Kinase inhibitors (BTKi) for both CLL and WM and BCL2 inhibito","cbCaifOX8hseJECs","https://ap.wps.com/l/cbCaifOX8hseJECs","pdf",1391529,13,"English","# Abstract\n## Background and Aims\n## Materials & Methods\n## Results\n## Discussion and Conclusion\n# Introduction\n## Disease overview and clinical management\n## Existing evidence and gaps","[{\"question\":\"What study objective is addressed in the abstract?\",\"answer\":\"To quantify incidence, prevalence, and relative survival and mortality for CLL/SLL and WM in Australia, and to report past trends.\"},{\"question\":\"Which time period and data sources were used for analysis?\",\"answer\":\"Cases registered from January 2009 to December 2018 across Victoria, Tasmania, Australian Capital Territory, and Queensland were identified from registries.\"},{\"question\":\"What survival outcomes were reported for CLL/SLL and WM?\",\"answer\":\"Kaplan–Meier estimates showed 10-year survival rates of 53% for CLL/SLL and 42% for WM at the end of the available data period (2018).\"},{\"question\":\"How were incidence trends analysed and projected into the future?\",\"answer\":\"Incidence rates for 2009–2018 were calculated and then projected to 2038 using linear regression.\"}]","Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia | PDF",1790147018,33,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c504cb2a290d79d361dccfeedb6044e.webp",983,1291,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/75fc095aa6a4e29a59ef5e3a1c8e4c02.webp",982,1290,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8be40aec4ae59f079068040e63922fb.webp",981,1289,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14925e5b4640a2759569fe3a05bbe21e.webp",980,1287]